Toronto - Delayed Quote CAD

Cardiol Therapeutics Inc. (CRDL.TO)

1.6200 -0.0400 (-2.41%)

At close: October 30 at 4:00:00 PM EDT

Chart Range Bar

Loading chart for CRDL.TO

Previous Close 1.6600
Open 1.6500
Bid 1.5700 x --
Ask 1.6300 x --
Day's Range 1.5450 - 1.6500
52 Week Range 1.2250 - 3.2300
Volume 117,589
Avg. Volume 250,516
Market Cap (intraday) 196.851M
Beta (5Y Monthly) 0.65
PE Ratio (TTM) --
EPS (TTM) -0.3400
Earnings Date (est.) Nov 12, 2026
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date --
1y Target Est 7.00

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

www.cardiolrx.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

CRDL.TO

23.66%

S&P/TSX Composite index (^GSPTSE)

11.78%

1-Year Return

CRDL.TO

5.88%

S&P/TSX Composite index (^GSPTSE)

18.03%

3-Year Return

CRDL.TO

39.66%

S&P/TSX Composite index (^GSPTSE)

88.90%

5-Year Return

CRDL.TO

64.00%

S&P/TSX Composite index (^GSPTSE)

69.32%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY26

Revenue --

Earnings -10.82M

Profit Margin 0.00%

FY25

FY26

-10M

-8M

-6M

-4M

-2M

0.0%

Analyst Price Targets

7.00

7.00 Average

1.6200 Current

7.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 9/23/2026

Analyst HC Wainwright & Co.

Rating Action Reiterates

Rating Buy

Price Action Maintains

Price Target 9 -> 9

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-90.92%
Return on Equity (ttm)

-190.18%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-34.08M
Diluted EPS (ttm)

-0.3400

Balance Sheet and Cash Flow

Total Cash (mrq)

26.08M
Total Debt/Equity (mrq)

0.44%
Levered Free Cash Flow (ttm)

-15.48M

MDNA.TO

AVCN.TO

LABS.TO

CRDL

CWEB.TO

U.S. markets open in 46m

Cardiol Therapeutics Inc. (CRDL.TO)

1.89%

-31.65%

-12.90%

23.66%

5.88%

-64.00%

-66.80%

Cardiol Therapeutics Inc. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch